Ayala Pharmaceuticals Inc Stock News

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 53.2% to close at $3.14 on Wednesday. Blue Water Vaccines recently announced signing of sponsored research agreement with Cincinnati Ch

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 67.8% to $3.4390. Blue Water Vaccines recently announced signing of sponsored research agreement with Cincinnati Children's Hospital Med

Gainers Dave Inc. (NASDAQ: DAVE) rose 56.9% to $0.9826 in pre-market trading. Dave is expected to release its second quarter 2022 financial results on Thursday, August 11, 2022. Pzena Investment Mana

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1. Pag

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 200 points on Tuesday. The Dow traded down 0.46% to 31,842.46 while the NASDAQ fell 1.80% to 11,571.14.

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) jumped 130% to $2.0001 after the company filed a request for the withdrawal of the Registration Statement on Form S-1. Sunshine Biopharma, Inc. (NAS

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 200 points on Tuesday. The Dow traded down 0.58% to 31,803.45 while the NASDAQ fell 1.71% to 11,581.11. The S

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) rose 64.4% to $1.43 in pre-market trading. Ayala Pharmaceuticals filed request for withdrawal of registration statement on form S-1. McEwen Mining I

REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small mo

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 7.04% and 57.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st

Interim data from Part A of RINGSIDE study of AL102 expected mid-2022 Interim data from Part A of RINGSIDE study of AL102 expected mid-2022

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 7.04% and 57.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of -43.33% and 27.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s

REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 1.49% and 32.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the